These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9834225)

  • 1. Identification of peptides, selected by phage display technology, that inhibit von Willebrand factor binding to collagen.
    Depraetere H; Viaene A; Deroo S; Vauterin S; Deckmyn H
    Blood; 1998 Dec; 92(11):4207-11. PubMed ID: 9834225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction.
    Vanhoorelbeke K; Depraetere H; Romijn RA; Huizinga EG; De Maeyer M; Deckmyn H
    J Biol Chem; 2003 Sep; 278(39):37815-21. PubMed ID: 12855711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence alignment between vWF and peptides inhibiting the vWF-collagen interaction does not result in the identification of a collagen-binding site in vWF.
    Vanhoorelbeke K; van der Plas RM; Vandecasteele G; Vauterin S; Huizinga EG; Sixma JJ; Deckmyn H
    Thromb Haemost; 2000 Oct; 84(4):621-5. PubMed ID: 11057860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of phages that inhibit vWF interaction with collagen under both static and flow conditions.
    Ulrichts H; Depraetere H; Harsfalvi J; Deckmyn H
    Thromb Haemost; 2001 Aug; 86(2):630-5. PubMed ID: 11522014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a VWF peptide antagonist that blocks platelet adhesion under high shear conditions by selectively inhibiting the VWF-collagen interaction.
    Szanto T; Vanhoorelbeke K; Toth G; Vandenbulcke A; Toth J; Noppe W; Deckmyn H; Harsfalvi J
    J Thromb Haemost; 2009 Oct; 7(10):1680-7. PubMed ID: 19624458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Willebrand factor binds to native collagen VI primarily via its A1 domain.
    Hoylaerts MF; Yamamoto H; Nuyts K; Vreys I; Deckmyn H; Vermylen J
    Biochem J; 1997 May; 324 ( Pt 1)(Pt 1):185-91. PubMed ID: 9164855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib.
    Obert B; Houllier A; Meyer D; Girma JP
    Blood; 1999 Mar; 93(6):1959-68. PubMed ID: 10068669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of peptide antagonists to glycoprotein Ibalpha that selectively inhibit von Willebrand factor dependent platelet aggregation.
    Benard SA; Smith TM; Cunningham K; Jacob J; DeSilva T; Lin L; Shaw GD; Kriz R; Kelleher KS
    Biochemistry; 2008 Apr; 47(16):4674-82. PubMed ID: 18363340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel peptide antagonists for von Willebrand factor binding to the platelet glycoprotein Ib receptor from a phage epitope library.
    South V; Searfoss GH; French S; Cheadle C; Murray E; Howk R; Jaye M; Ricca GA
    Thromb Haemost; 1995 Jan; 73(1):144-50. PubMed ID: 7537918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adhesive domains in the collagen III fragment alpha1(III)CB4 that support alpha2beta1- and von Willebrand factor-mediated platelet adhesion under flow conditions.
    Verkleij MW; IJsseldijk MJ; Heijnen-Snyder GJ; Huizinga EG; Morton LF; Knight CG; Sixma JJ; de Groot PG; Barnes MJ
    Thromb Haemost; 1999 Sep; 82(3):1137-44. PubMed ID: 10494778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons.
    Wu D; Vanhoorelbeke K; Cauwenberghs N; Meiring M; Depraetere H; Kotze HF; Deckmyn H
    Blood; 2002 May; 99(10):3623-8. PubMed ID: 11986216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides.
    Cruz MA; Yuan H; Lee JR; Wise RJ; Handin RI
    J Biol Chem; 1995 May; 270(18):10822-7. PubMed ID: 7738019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental indication for the existence of multiple Trp rotamers in von Willebrand Factor A3 domain.
    Hellings M; Engelborghs Y; Deckmyn H; Vanhoorelbeke K; Schiphorst ME; Akkerman JW; De Maeyer M
    Proteins; 2004 Nov; 57(3):596-601. PubMed ID: 15382239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding site on human von Willebrand factor of bitiscetin, a snake venom-derived platelet aggregation inducer.
    Matsui T; Hamako J; Matsushita T; Nakayama T; Fujimura Y; Titani K
    Biochemistry; 2002 Jun; 41(25):7939-46. PubMed ID: 12069583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of the A3 domain of human von Willebrand factor: implications for collagen binding.
    Huizinga EG; Martijn van der Plas R; Kroon J; Sixma JJ; Gros P
    Structure; 1997 Sep; 5(9):1147-56. PubMed ID: 9331419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A3 domain is essential for interaction of von Willebrand factor with collagen type III.
    Lankhof H; van Hoeij M; Schiphorst ME; Bracke M; Wu YP; Ijsseldijk MJ; Vink T; de Groot PG; Sixma JJ
    Thromb Haemost; 1996 Jun; 75(6):950-8. PubMed ID: 8822592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Localization of a collagen-interactive domain of human von Willebrand factor between amino acid residues Gly 911 and Glu 1,365.
    Kalafatis M; Takahashi Y; Girma JP; Meyer D
    Blood; 1987 Nov; 70(5):1577-83. PubMed ID: 2889486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody inhibits binding of von Willebrand factor to glycoprotein Ib and collagen in multiple myeloma: recognition sites present on the A1 loop and A3 domains of von Willebrand factor.
    Mohri H; Hisanaga S; Mishima A; Fujimoto S; Uezono S; Okubo T
    Blood Coagul Fibrinolysis; 1998 Jan; 9(1):91-7. PubMed ID: 9607124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen.
    van Genderen PJ; Vink T; Michiels JJ; van 't Veer MB; Sixma JJ; van Vliet HH
    Blood; 1994 Nov; 84(10):3378-84. PubMed ID: 7949092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of antibodies that interfere with the collagen-VWF-GPIb axis as new antithrombotics.
    Deckmyn H; Cauwenberghs N; Wu D; Depraetere H; Vanhoorelbeke K
    Verh K Acad Geneeskd Belg; 2005; 67(1):55-65. PubMed ID: 15828307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.